134.11 14.03 Shares of gain (loss) from investments in an associate and a joint venture (1.31) 13.63 0.00 0.00 Gain from change in a joint venture proportion 0.00 (9.87) 0.00 0.00 Gain on sale of

instruments 184.90 12.08 184.90 12.08 Shares of gain (loss) from investments in an associate and a joint venture (0.43) 19.16 0.00 0.00 Gain from change in a joint venture proportion 0.00 (9.87) 0.00 0.00 Gain

regarding the acquisition of assets. (Amendment) 18/10/2021 17:46 Resolutions of the Board of Directors Meeting No. 7/2021 regarding the acquisition of assets. 23/07/2021 13:47 Notification on the change a

time because most of the license entities still use the same method taking about 5 to 7 days until the clients could start their investment, this results in a burden for the accessibility to the

partly from the change due to TFRS 9 interest income calculation based on effective interest method. Yield on loan for 3Q20 increased slightly to 7.1% from 7.0% yoy. Interest expense totaled Baht 1,175

www.interpharma.co.th IP_OCS/011/2020 8th June 2020 Subject: Notify the Resolutions of the Board of Directors Meeting, Change of Objectives of Funds Usage, Acquisition of Assets, The Issuance of Debentures and Fix the

until the gross profit being reported differently from the previous periods Operating Highlights in Q4/2019 & 2019 Q4/18 Q3/19 Q4/19 Change +/(-) 2018 2019 Change+/(-) (Unit: Million Baht) QoQ YoY

in the nine-month period of the year 2018. The change was due to the decreased lease receivable, calculated according to the Effective Interest Method. 3.3 Cost of sales and rendering of services

., BANGKAE, BANGKAE, BANGKOK, THAILAND. 10160 Tel: 02-455-2888 Fax: 02-455-2763 (“TRANSLATION”) TG 052/2020 May 11, 2020 Subject: Clarification of the Operating Result for the significant change Attention: The

income and cost of sales resultin g in the operating income until the gross profit being reported differently from the previous periods Operating Highlights in Q3/2019 Q3/18 Q2/192 Q3/19 Change +/(-) 9M/18